174 related articles for article (PubMed ID: 24499802)
1. Evaluation of von Willebrand factor and von Willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury.
Brott DA; Katein A; Thomas H; Lawton M; Montgomery RR; Richardson RJ; Louden CS
Toxicol Pathol; 2014 Jun; 42(4):672-83. PubMed ID: 24499802
[TBL] [Abstract][Full Text] [Related]
2. von Willebrand factor propeptide to antigen ratio identifies platelet activation and reduced von Willebrand factor survival phenotype in mice.
Jacobi PM; Kanaji S; Jakab D; Gehrand AL; Johnsen JM; Haberichter SL
J Thromb Haemost; 2018 Mar; 16(3):546-554. PubMed ID: 29285851
[TBL] [Abstract][Full Text] [Related]
3. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation.
Ward SE; Curley GF; Lavin M; Fogarty H; Karampini E; McEvoy NL; Clarke J; Boylan M; Alalqam R; Worrall AP; Kelly C; de Barra E; Glavey S; Ni Cheallaigh C; Bergin C; Martin-Loeches I; Townsend L; Mallon PW; O'Sullivan JM; O'Donnell JS;
Br J Haematol; 2021 Feb; 192(4):714-719. PubMed ID: 33326604
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide studies of von Willebrand factor propeptide identify loci contributing to variation in propeptide levels and von Willebrand factor clearance.
Ozel AB; McGee B; Siemieniak D; Jacobi PM; Haberichter SL; Brody LC; Mills JL; Molloy AM; Ginsburg D; Li JZ; Desch KC
J Thromb Haemost; 2016 Sep; 14(9):1888-98. PubMed ID: 27359253
[TBL] [Abstract][Full Text] [Related]
5. von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation.
van Mourik JA; Boertjes R; Huisveld IA; Fijnvandraat K; Pajkrt D; van Genderen PJ; Fijnheer R
Blood; 1999 Jul; 94(1):179-85. PubMed ID: 10381511
[TBL] [Abstract][Full Text] [Related]
6. von Willebrand factor propeptide: biology and clinical utility.
Haberichter SL
Blood; 2015 Oct; 126(15):1753-61. PubMed ID: 26215113
[TBL] [Abstract][Full Text] [Related]
7. Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease.
Casonato A; Daidone V; Padrini R
Semin Thromb Hemost; 2011 Jul; 37(5):456-63. PubMed ID: 22102187
[TBL] [Abstract][Full Text] [Related]
8. Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage.
Haberichter SL; Jacobi P; Montgomery RR
Blood; 2003 Feb; 101(4):1384-91. PubMed ID: 12393513
[TBL] [Abstract][Full Text] [Related]
9. Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status.
Lee A; Sinclair G; Valentine K; James P; Poon MC
Blood; 2014 Jul; 124(5):e1-3. PubMed ID: 24951428
[TBL] [Abstract][Full Text] [Related]
10. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome.
van Genderen PJ; Boertjes RC; van Mourik JA
Thromb Haemost; 1998 Sep; 80(3):495-8. PubMed ID: 9759633
[TBL] [Abstract][Full Text] [Related]
12. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
[TBL] [Abstract][Full Text] [Related]
13. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
14. von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion.
Madabhushi SR; Shang C; Dayananda KM; Rittenhouse-Olson K; Murphy M; Ryan TE; Montgomery RR; Neelamegham S
Blood; 2012 May; 119(20):4769-78. PubMed ID: 22452980
[TBL] [Abstract][Full Text] [Related]
15. Differential intracellular trafficking of von Willebrand factor (vWF) and vWF propeptide in porcine endothelial cells lacking Weibel-Palade bodies and in human endothelial cells.
Royo T; Martínez-González J; Vilahur G; Badimon L
Atherosclerosis; 2003 Mar; 167(1):55-63. PubMed ID: 12618268
[TBL] [Abstract][Full Text] [Related]
16. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
Haberichter SL; Castaman G; Budde U; Peake I; Goodeve A; Rodeghiero F; Federici AB; Batlle J; Meyer D; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Ingerslev J; Vorlova Z; Habart D; Holmberg L; Lethagen S; Pasi J; Hill FG; Montgomery RR
Blood; 2008 May; 111(10):4979-85. PubMed ID: 18344424
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.
Stufano F; Boscarino M; Bucciarelli P; Baronciani L; Maino A; Cozzi G; Peyvandi F
Semin Thromb Hemost; 2019 Feb; 45(1):36-42. PubMed ID: 29913537
[TBL] [Abstract][Full Text] [Related]
18. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.
Eikenboom J; Federici AB; Dirven RJ; Castaman G; Rodeghiero F; Budde U; Schneppenheim R; Batlle J; Canciani MT; Goudemand J; Peake I; Goodeve A;
Blood; 2013 Mar; 121(12):2336-9. PubMed ID: 23349392
[TBL] [Abstract][Full Text] [Related]
19. Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome.
Ito-Habe N; Wada H; Matsumoto T; Ohishi K; Toyoda H; Ishikawa E; Nomura S; Komada Y; Ito M; Nobori T; Katayama N
Int J Hematol; 2011 Jan; 93(1):47-52. PubMed ID: 21153061
[TBL] [Abstract][Full Text] [Related]
20. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease.
Sztukowska M; Gallinaro L; Cattini MG; Pontara E; Sartorello F; Daidone V; Padrini R; Pagnan A; Casonato A
Br J Haematol; 2008 Oct; 143(1):107-14. PubMed ID: 18691167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
